Form D · Biotechnology
SYNDEVRX INC
Cambridge, MA · CIK 0001455364
Offering snapshot reported Dec 23, 2025 · SEC filing
- Reported sold
- $6.47M Offering amount: $20M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 4, 2024 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 23, 2025 | Amendment | $6,467,100 | $0vs Nov 17, 2025 | 7 | SEC filing |
| Nov 17, 2025 | Amendment | $6,467,100 | $5,489,100vs Nov 15, 2024 | 7 | SEC filing |
| Nov 15, 2024 | Initial | $978,000 | No comparison | 5 | SEC filing |
| Oct 10, 2024 | Initial | $29,354,820 | No comparison | 13 | SEC filing |
| Dec 20, 2023 | Amendment | $23,249,350 | $4,804,623vs Dec 14, 2022 | 7 | SEC filing |
| Dec 14, 2022 | Amendment | $18,444,727 | $3,772,513vs Dec 30, 2021 | 6 | SEC filing |
| Dec 30, 2021 | Amendment | $14,672,214 | $5,475,214vs Jan 15, 2021 | 7 | SEC filing |
| Jan 15, 2021 | Amendment | $9,197,000 | $3,097,000vs Jan 17, 2020 | 7 | SEC filing |
| Jan 17, 2020 | Initial | $6,100,000 | No comparison | 6 | SEC filing |
| Mar 19, 2019 | Amendment | $850,000 | $350,000vs Mar 21, 2018 | 4 | SEC filing |
| Mar 21, 2018 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Nov 9, 2017 | Amendment | $1,500,000 | $1,000,000vs Aug 15, 2017 | 1 | SEC filing |
| Aug 15, 2017 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Mar 20, 2017 | Amendment | $16,285,471 | $2,875,250vs Jul 13, 2016 | 40 | SEC filing |
| Jul 13, 2016 | Amendment | $13,410,221 | $1,000,000vs Apr 28, 2016 | 38 | SEC filing |
| Apr 28, 2016 | Amendment | $12,410,221 | $1,103,575vs Sep 15, 2015 | 38 | SEC filing |
| Sep 15, 2015 | Amendment | $11,306,646 | $9,093,899vs Dec 20, 2013 | 38 | SEC filing |
| Dec 20, 2013 | Amendment | $2,212,747 | $602,747vs May 31, 2013 | 27 | SEC filing |
| May 31, 2013 | Amendment | $1,610,000 | $1,595,000vs Nov 8, 2012 | 8 | SEC filing |
| Nov 8, 2012 | Initial | $15,000 | No comparison | 2 | SEC filing |
| Jul 27, 2010 | Amendment | $225,000 | $145,000vs May 24, 2010 | 10 | SEC filing |
| Jul 20, 2010 | Amendment | $1,294,659 | $725,000vs Jul 23, 2009 | 11 | SEC filing |
| May 24, 2010 | Initial | $80,000 | No comparison | 7 | SEC filing |
| Jul 23, 2009 | Initial | $569,659 | No comparison | 11 | SEC filing |
| Jan 29, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-529572
Source: Form D, filed Dec 23, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bradley J Carver | Director, Executive |
| Michael Clifford | Director |
| Charlie Flynn | Director |
| Charles Flynn | Director |
| Richard Love | Director |
| David Neafus | Executive |
| John Petersen | Executive |
| John Peterson | Executive |
| Joanne Schindler | Executive |
| James Michael Shanahan | Director, Executive |
| Eric Tooker | Director |
| Jeffrey Welles | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:Cambridge, MA, 02142